Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Correction: Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality.

Szmyd R, Niska-Blakie J, Diril MK, Nunes PR, Tzelepis K, Lacroix A, van Hul N, Deng LW, Matos J, Dreesen O, Bisteau X, Kaldis P.

Oncogene. 2019 Nov 21. doi: 10.1038/s41388-019-1114-x. [Epub ahead of print]

PMID:
31754212
2.

RNA-modifying enzymes and their function in a chromatin context.

Tzelepis K, Rausch O, Kouzarides T.

Nat Struct Mol Biol. 2019 Oct;26(10):858-862. doi: 10.1038/s41594-019-0312-0. Epub 2019 Oct 3. Review.

PMID:
31582848
3.

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS.

Nat Commun. 2018 Dec 19;9(1):5378. doi: 10.1038/s41467-018-07620-0.

4.

Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality.

Szmyd R, Niska-Blakie J, Diril MK, Renck Nunes P, Tzelepis K, Lacroix A, van Hul N, Deng LW, Matos J, Dreesen O, Bisteau X, Kaldis P.

Oncogene. 2019 Feb;38(7):998-1018. doi: 10.1038/s41388-018-0464-0. Epub 2018 Sep 6. Erratum in: Oncogene. 2019 Nov 21;:.

5.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Northcott PA, Adams D, Vassiliou GS, Huntly BJP.

Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z. Epub 2018 May 7.

6.

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.

Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C, Huntly BJP.

Blood. 2018 Apr 12;131(15):1639-1653. doi: 10.1182/blood-2017-12-820035. Epub 2018 Feb 20.

7.

Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control.

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, De Braekeleer E, Ponstingl H, Hendrick A, Vakoc CR, Vassiliou GS, Kouzarides T.

Nature. 2017 Dec 7;552(7683):126-131. doi: 10.1038/nature24678. Epub 2017 Nov 27.

8.

Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.

Dovey OM, Cooper JL, Mupo A, Grove CS, Lynn C, Conte N, Andrews RM, Pacharne S, Tzelepis K, Vijayabaskar MS, Green P, Rad R, Arends M, Wright P, Yusa K, Bradley A, Varela I, Vassiliou GS.

Blood. 2017 Oct 26;130(17):1911-1922. doi: 10.1182/blood-2017-01-760595. Epub 2017 Aug 23.

9.

Enhancing the genome editing toolbox: genome wide CRISPR arrayed libraries.

Metzakopian E, Strong A, Iyer V, Hodgkins A, Tzelepis K, Antunes L, Friedrich MJ, Kang Q, Davidson T, Lamberth J, Hoffmann C, Davis GD, Vassiliou GS, Skarnes WC, Bradley A.

Sci Rep. 2017 May 22;7(1):2244. doi: 10.1038/s41598-017-01766-5.

10.

Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.

Mupo A, Seiler M, Sathiaseelan V, Pance A, Yang Y, Agrawal AA, Iorio F, Bautista R, Pacharne S, Tzelepis K, Manes N, Wright P, Papaemmanuil E, Kent DG, Campbell PC, Buonamici S, Bolli N, Vassiliou GS.

Leukemia. 2017 Mar;31(3):720-727. doi: 10.1038/leu.2016.251. Epub 2016 Sep 8.

11.

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS, Yusa K.

Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079.

12.

Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.

Mylona E, Melissaris S, Nomikos A, Theohari I, Giannopoulou I, Tzelepis K, Nakopoulou L.

Pathol Res Pract. 2014 Aug;210(8):533-40. doi: 10.1016/j.prp.2014.05.009. Epub 2014 May 23.

PMID:
24947414
13.

Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype.

Mylona E, Tzelepis K, Theohari I, Giannopoulou I, Papadimitriou C, Nakopoulou L.

Histopathology. 2013 Feb;62(3):472-80. doi: 10.1111/his.12013. Epub 2012 Nov 16.

PMID:
23163571
14.

Detection of circulating tumor cells in bladder cancer patients.

Nezos A, Pissimisis N, Lembessis P, Sourla A, Dimopoulos P, Dimopoulos T, Tzelepis K, Koutsilieris M.

Cancer Treat Rev. 2009 May;35(3):272-9. doi: 10.1016/j.ctrv.2008.11.003. Epub 2008 Dec 21. Review.

PMID:
19103472

Supplemental Content

Loading ...
Support Center